Health IT vendor IMS Health and biopharmaceutical research firm Quintiles Transnational Holdings have agreed to merge.
Per the agreement, the companies will be combined in an all-stock merger of equals, with the merged company to be named Quintiles IMS Holdings.
The new company seeks to create one of the largest portfolios of healthcare information and to drive insights and efficiencies across the life sciences product lifecycle.
"This combination addresses life science companies' most pressing needs: to transform the clinical development of innovative medicines, demonstrate the value of these medicines in the real world and drive commercial success," said Tom Pike, Quintiles CEO, in a statement.
Mr. Pike will become vice chairman of the merged organization, and IMS Health chairman and CEO Ari Bousbib will become chairman and CEO of the merged organization. The company plans to maintain dual headquarters in Danbury, Conn., and Research Triangle Park, N.C.
More articles on health IT:
City of Verona to close Epic's campus TIF district, will collect $21.2M
24 hospitals, health systems seeking Cerner, MEDITECH, Epic talent
Not-so-sensitive data: The case for unprotected health information